Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity

  title={Topoisomerase 2$\beta$: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity},
  author={Pimprapa Vejpongsa and Eth Yeh},
  journal={Clinical Pharmacology \& Therapeutics},
  • P. Vejpongsa, Eth Yeh
  • Published 19 December 2013
  • Chemistry, Biology, Medicine
  • Clinical Pharmacology & Therapeutics
Anthracyclines are powerful chemotherapy agents that are still widely used today. However, their clinical use is limited by the development of dose‐dependent cardiotoxicity. Recently, we showed that topoisomerase 2β (Top2β) is required for anthracycline to induce DNA double‐strand breaks and changes in the transcriptome, leading to mitochondrial dysfunction and generation of reactive oxygen species. Furthermore, deleting Top2β from cardiomyocytes prevented the development of anthracycline… 
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
Off-label use of statins or novel Rac1 inhibitors might represent a promising pharmacological approach to gain control over chronic cardiotoxicity by interfering with key mechanisms of anthracycline-induced cardiomyocyte cell death.
Cardiotoxicity of anthracycline therapy: current perspectives
According to previous clinical trials, the major high-risk factors for anthracycline-induced cardiotoxicity are age, body weight, female gender, radiotherapy, and other diseases such as Down syndrome, familial dilated cardiomyopathy, diabetes and hypertension.
A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
The therapeutic value of 6h as a promising chemotherapy for cancers is supported after several rounds of structural optimizations on the in-house topo II inhibitor E17, which was shown to have superior anticancer activity and less risk of multidrug resistance.
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
  • R. Damiani, D. Moura, J. Saffi
  • Biology, Chemistry
    Toxicology in vitro : an international journal published in association with BIBRA
  • 2018
Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation.
The present review aimed to discuss ANTs-induced cardiac injury from different points of view, updating and focusing on oxidative stress and inflammation, since these pathways are not exclusive or independent from each other but they together importantly contribute to the complexity of AN Ts-induced multifactorial cardiotoxicity.
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation
This study strongly supports a new mechanistic paradigm that attributes clinically effective cardioprotection against anthracycline cardiotoxicity to interactions with TOP2B but not metal chelation and protection against direct oxidative damage.
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity
This work reviews the pathogenic mechanisms of doxorubicin-induced cardiotoxicity and presents an update on cardioprotective strategies for this disorder and focuses on strategies that can protect the mitochondria and cover different therapeutic modalities encompassing small molecules, post-transcriptional regulators, and mitochondrial transfer.
Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis
The purpose of this review is to summarize the historical background that led to each form of cell death, focusing on DOX-induced cardiotoxicity and the molecular mechanisms that trigger each form to cardiomyocyte death.


Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
It is shown that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes, and this results suggest that dex Razoxane antagonizesDoxorubsicin-induced DNA damage through its interference with Top2beta, which could implicate Top2 beta indoxorUBicin cardiotoxicity.
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
It is shown here that VP-16-induced carcinogenesis involves mainly the β rather than the α isozyme of Top2, suggesting the importance of developing Top2α-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*
It is shown that NK314, a novel synthetic benzo[c]phenanthridine alkaloid, targets Top2α and not Top2β in vivo, and that a series of human knock-out cell lines are useful in assessing DNA damage and repair induced by potential topoisomerase-targeting agents.
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation.
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
It is suggested that doxorubicin treatment induces acute cardiac dysfunction and reduces cardiac mass via p53-dependent inhibition of mTOR signaling and that loss of myocardial mass, and not cardiomyocyte apoptosis, is the major contributor to acute doxorbicin cardiotoxicity.
Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells
The expression level of topo II beta is intra- and inter-individually variable, and may in part determine the apoptotic response to doxorubicin and other anthracyclines.
Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Monitoring IRP activities in H9c2 rat embryo cardiomyocytes exposed to DOX or to analogues revealed that IRP-2 was inactivated only by ROS, serving guidelines for designing anthracyclines that spare iron homeostasis and induce less severe cardiotoxicity.